Pfizer Inc. (NYSE:PFE) Stock Holdings Lessened by First Citizens Financial Corp

First Citizens Financial Corp trimmed its stake in Pfizer Inc. (NYSE:PFE) by 6.1% in the third quarter, Holdings Channel.com reports. The firm owned 7,550 shares of the biopharmaceutical company’s stock after selling 492 shares during the quarter. First Citizens Financial Corp’s holdings in Pfizer were worth $218,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. LGT Group Foundation lifted its position in shares of Pfizer by 2.5% in the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock worth $20,786,000 after purchasing an additional 18,274 shares in the last quarter. ORG Partners LLC raised its holdings in shares of Pfizer by 1,729.9% during the 2nd quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock valued at $1,327,000 after purchasing an additional 44,458 shares in the last quarter. Kempner Capital Management Inc. acquired a new stake in shares of Pfizer in the 1st quarter valued at $2,439,000. Leo Wealth LLC bought a new stake in Pfizer in the fourth quarter worth $2,171,000. Finally, Power Corp of Canada increased its position in Pfizer by 28.1% during the fourth quarter. Power Corp of Canada now owns 174,201 shares of the biopharmaceutical company’s stock worth $5,015,000 after buying an additional 38,243 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on PFE. UBS Group boosted their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Thursday. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, StockNews.com downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday. Nine investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Stock Down 0.9 %

PFE stock opened at $28.35 on Friday. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $34.08. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The company has a market cap of $160.65 billion, a PE ratio of -472.50, a price-to-earnings-growth ratio of 1.25 and a beta of 0.67. The business’s 50-day simple moving average is $29.21 and its 200 day simple moving average is $28.31.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. Pfizer’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.67 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.